Canada
Novelogics Biotechnology Inc. is a pre-clinical stage biotech company headquartered in Vancouver, Canada, focusing on developing a novel monoclonal antibody immunotherapy drug for cancer treatment. Founded in 2013, the company leverages its unique "Interceptor" approach to target proteins that suppress the immune system, aiming to enhance how the body detects and destroys cancer cells.
The drug addresses multiple cancer types — including solid tumors and blood cancers — significantly broadening its market potential. Novelogics seeks to provide a safer treatment avenue while preserving patient quality of life.
Despite its promising vision, Novelogics has not had recent major investment activity, with its last recorded funding being an Angel Round from Angel Forum on January 1, 2014. With over a decade of operations, securing further investment could be pivotal in advancing their current stage and entering clinical trials.
